Cargando…
A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991276/ http://dx.doi.org/10.1186/2051-1426-1-S1-P219 |
| _version_ | 1782312406814294016 |
|---|---|
| author | Kallen, Karl-Josef Gnad-Vogt, Ulrike Scheel, Birgit Rippin, Gerd Stenzl, Arnulf |
| author_facet | Kallen, Karl-Josef Gnad-Vogt, Ulrike Scheel, Birgit Rippin, Gerd Stenzl, Arnulf |
| author_sort | Kallen, Karl-Josef |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3991276 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-39912762014-05-05 A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses Kallen, Karl-Josef Gnad-Vogt, Ulrike Scheel, Birgit Rippin, Gerd Stenzl, Arnulf J Immunother Cancer Poster Presentation BioMed Central 2013-11-07 /pmc/articles/PMC3991276/ http://dx.doi.org/10.1186/2051-1426-1-S1-P219 Text en Copyright © 2013 Kallen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Poster Presentation Kallen, Karl-Josef Gnad-Vogt, Ulrike Scheel, Birgit Rippin, Gerd Stenzl, Arnulf A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses |
| title | A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses |
| title_full | A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses |
| title_fullStr | A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses |
| title_full_unstemmed | A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses |
| title_short | A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses |
| title_sort | phase i/iia study of the mrna based cancer vaccine cv9103 prepared with the rnactive technology results in distinctly longer survival than predicted by the halabi nomogram which correlates with the induction of antigen-specific immune responses |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991276/ http://dx.doi.org/10.1186/2051-1426-1-S1-P219 |
| work_keys_str_mv | AT kallenkarljosef aphaseiiiastudyofthemrnabasedcancervaccinecv9103preparedwiththernactivetechnologyresultsindistinctlylongersurvivalthanpredictedbythehalabinomogramwhichcorrelateswiththeinductionofantigenspecificimmuneresponses AT gnadvogtulrike aphaseiiiastudyofthemrnabasedcancervaccinecv9103preparedwiththernactivetechnologyresultsindistinctlylongersurvivalthanpredictedbythehalabinomogramwhichcorrelateswiththeinductionofantigenspecificimmuneresponses AT scheelbirgit aphaseiiiastudyofthemrnabasedcancervaccinecv9103preparedwiththernactivetechnologyresultsindistinctlylongersurvivalthanpredictedbythehalabinomogramwhichcorrelateswiththeinductionofantigenspecificimmuneresponses AT rippingerd aphaseiiiastudyofthemrnabasedcancervaccinecv9103preparedwiththernactivetechnologyresultsindistinctlylongersurvivalthanpredictedbythehalabinomogramwhichcorrelateswiththeinductionofantigenspecificimmuneresponses AT stenzlarnulf aphaseiiiastudyofthemrnabasedcancervaccinecv9103preparedwiththernactivetechnologyresultsindistinctlylongersurvivalthanpredictedbythehalabinomogramwhichcorrelateswiththeinductionofantigenspecificimmuneresponses AT kallenkarljosef phaseiiiastudyofthemrnabasedcancervaccinecv9103preparedwiththernactivetechnologyresultsindistinctlylongersurvivalthanpredictedbythehalabinomogramwhichcorrelateswiththeinductionofantigenspecificimmuneresponses AT gnadvogtulrike phaseiiiastudyofthemrnabasedcancervaccinecv9103preparedwiththernactivetechnologyresultsindistinctlylongersurvivalthanpredictedbythehalabinomogramwhichcorrelateswiththeinductionofantigenspecificimmuneresponses AT scheelbirgit phaseiiiastudyofthemrnabasedcancervaccinecv9103preparedwiththernactivetechnologyresultsindistinctlylongersurvivalthanpredictedbythehalabinomogramwhichcorrelateswiththeinductionofantigenspecificimmuneresponses AT rippingerd phaseiiiastudyofthemrnabasedcancervaccinecv9103preparedwiththernactivetechnologyresultsindistinctlylongersurvivalthanpredictedbythehalabinomogramwhichcorrelateswiththeinductionofantigenspecificimmuneresponses AT stenzlarnulf phaseiiiastudyofthemrnabasedcancervaccinecv9103preparedwiththernactivetechnologyresultsindistinctlylongersurvivalthanpredictedbythehalabinomogramwhichcorrelateswiththeinductionofantigenspecificimmuneresponses |